利培酮治疗自闭症谱系障碍儿童"治疗窗"的外部验证
发布日期:
2026-11-16
浏览次数:
0

自闭症谱系障碍(ASD)以社交沟通缺陷和重复刻板行为为特征[1]。为控制共病的易激惹与攻击行为,利培酮(risperidone)是首选的非典型抗精神病药[2],指南建议ASD儿童起始0.01 mg/kg/天、最大3.0 mg/天。但利培酮在有效的同时刺激代谢系统,常引起体重增加、泌乳素与血脂升高等副作用[3]。成人TDM治疗窗为20–60 ng/mL[4],儿童用于精神病与冲动攻击症状的参考范围为9–33与8–26 ng/mL[5, 6]。SPACe研究团队建立了利培酮及其活性代谢物9-OH-利培酮的群体药代动力学(popPK)模型,将稳态谷浓度之和与体重增加及疗效关联[7],算出3.5–7.0 ng/mL的治疗窗[8],本研究即用独立数据对该模型与治疗窗进行外部验证。


方法与结果

利培酮治疗自闭症谱系障碍儿童"治疗窗"的外部验证

方法

数据来自德国TDM-VIGIL研究与维尔茨堡大学TDM常规服务数据库,纳入6–18岁、达稳态且数据完整的ASD相关患儿。采用非线性混合效应建模对SPACe popPK模型进行外部验证,以拟合优度图与视觉预测检验(VPC)评估模型性能[9];以BMI z-score较基线的增幅界定上限切点[10]、以临床总体印象量表(CGI)1–2分界定下限切点[11],并经ROC曲线确定治疗窗上下限。

结果

共纳入TDM-VIGIL研究48例与TDM服务151例,其中46例数据适合进一步分析,仅10例信息完整可纳入上下限分析。模型验证使用46例、68次利培酮浓度(中位3.0 ng/mL)与64次9-OH-利培酮浓度(中位8.0 ng/mL),中位剂量1.50 mg。无论GoF图还是VPC,模型对9-OH-利培酮的预测均优于原型利培酮:利培酮常被低估,9-OH-利培酮有时被高估(图1)。上限分析的10例中位剂量0.75 mg、稳态谷浓度之和6.5 ng/mL,出现显著体重增加的7例浓度之和偏高但无统计学意义(P=.86),ROC给出5.0 ng/mL切点(AUC=0.74,图2A)。下限分析的10例中位剂量0.63 mg、浓度之和7.5 ng/mL,治疗有效的6例浓度之和偏高但同样不显著(P=.24),除1例外均高于SPACe下限3.5 ng/mL,ROC给出5.0 ng/mL切点(AUC=0.67,图2B)。由于上下限切点相同(均为5.0 ng/mL),进一步评估后取ROC曲线上第二远离敏感/特异线的点作为上限(8.0 ng/mL),故治疗窗最终定为5.0–8.0 ng/mL。

利培酮治疗自闭症谱系障碍儿童"治疗窗"的外部验证

图1  群体药代动力学模型验证的视觉预测检验(VPC),分层展示利培酮与9-OH-利培酮两个房室;实红线为观测值第50百分位,两虚红线为第2.5与97.5百分位,蓝色与灰色阴影分别为模型模拟值的95%置信区间

利培酮治疗自闭症谱系障碍儿童"治疗窗"的外部验证


图2  稳态谷浓度之和的箱线图:(A) 按随访时长对应的BMI z-score切点分组,(B) 按治疗是否有效分组;红色水平线为SPACe研究治疗窗的切点值


讨论

本研究对SPACe研究的模型与治疗窗进行外部验证。以GoF和VPC发现,模型预测9-OH-利培酮优于利培酮,整体低估利培酮、高估9-OH-利培酮。这与Karatza等的研究一致——利培酮在各模型中均被低估,SPACe模型能有效预测9-OH-利培酮[12];因个体预测较准确,模型适用于TDM。治疗窗最终定为5.0–8.0 ng/mL;因上下限Youden指数同为5.0 ng/mL难以遵循,故上限改取ROC次优点,提示宜取低值以限制体重增加。该范围与既往3.5–7.0 ng/mL相当,但样本极小、低浓度点少(下限分析仅1例低于5.0 ng/mL),故不宜据此更改治疗窗,而应视为对"ASD儿童治疗窗显著低于成人及此前儿童参考范围"的验证[4-6] 。局限:数据并非为该分析而设计,需对采血时间与稳态做假设;每组仅10例使ROC结果需谨慎解读;TDM-VIGIL曾按成人20–60 ng/mL调整部分剂量[4]。本研究为SPACe模型与治疗窗的后续应用提供更强依据,当前SPACe 2: STAR研究正用其估算谷浓度并基于3.5–7.0 ng/mL提供给药建议[13];TDM给药时应注意模型低估利培酮浓度的倾向。


浓度监测全流程智慧解决方案

利培酮治疗自闭症谱系障碍儿童"治疗窗"的外部验证

参考文献

1.Sharma, S.R., X. Gonda, and F.I. Tarazi, Autism Spectrum Disorder: Classification, diagnosis and therapy. Pharmacol Ther, 2018. 190: p. 91-104.

2.Fung, L.K., et al., Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis. Pediatrics, 2016. 137 Suppl 2: p. S124-35.

3.Persico, A.M., A. Ricciardello, and F. Cucinotta, The psychopharmacology of autism spectrum disorder and Rett syndrome. Handb Clin Neurol, 2019. 165: p. 391-414.

4.Hiemke, C., et al., Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry, 2018. 51(1-02): p. 9-62.

5.Klampfl, K., et al., Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Pharmacopsychiatry, 2010. 43(2): p. 58-65.

6.Taurines, R., et al., Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone. J Neural Transm (Vienna), 2022. 129(5-6): p. 689-701.

7.Kloosterboer, S.M., et al., Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder. Br J Clin Pharmacol, 2021. 87(3): p. 1069-1081.

8.Hermans, R.A., et al., Therapeutic Drug Monitoring to Optimize Risperidone Treatment in Children with Autism Spectrum Disorder. Ther Drug Monit, 2024. 46(2): p. 259-264.

9.Bergstrand, M., et al., Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J, 2011. 13(2): p. 143-51.

10.van der Esch, C.C.L., et al., Risk factors and pattern of weight gain in youths using antipsychotic drugs. Eur Child Adolesc Psychiatry, 2021. 30(8): p. 1263-1271.

11.Busner, J. and S.D. Targum, The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont), 2007. 4(7): p. 28-37.

12.Karatza, E., et al., External Evaluation of Risperidone Population Pharmacokinetic Models Using Opportunistic Pediatric Data. Front Pharmacol, 2022. 13: p. 817276.

13.Hermans, R.A., et al., The effect of therapeutic drug monitoring of risperidone and aripiprazole on weight gain in children and adolescents: the SPACe 2: STAR (trial) protocol of an international multicentre randomised controlled trial. BMC Psychiatry, 2022. 22(1): p. 814.

14.Hermans, R.A., et al., External validation of a therapeutic window for risperidone in children with autism spectrum disorder. Br J Clin Pharmacol, 2025. 91(10): p. 3009-3015.




相关推荐